Biofrontera Stock Today
| BFRI Stock | USD 1.06 0.01 0.95% |
Performance3 of 100
| Odds Of DistressOver 82
|
Biofrontera is trading at 1.06 as of the 31st of January 2025. This is a 0.95 percent increase since the beginning of the trading day. The stock's open price was 1.05. Biofrontera has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of November 2024 and ending today, the 31st of January 2025. Click here to learn more.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. The company has 8.87 M outstanding shares of which 310.29 K shares are currently shorted by private and institutional investors with about 0.08 trading days to cover. More on Biofrontera
Moving together with Biofrontera Stock
| 0.61 | NBIX | Neurocrine Biosciences Earnings Call This Week | PairCorr |
Moving against Biofrontera Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Biofrontera Stock Highlights
| President CEO | Hermann Luebbert |
| Business Concentration | Pharmaceutical Products, Drug Manufacturers - Specialty & Generic, Healthcare, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Biofrontera (BFRI) is traded on NASDAQ Exchange in USA. It is located in 120 Presidential Way, Woburn, MA, United States, 01801 and employs 83 people. Biofrontera is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.41 M. Biofrontera conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.87 M outstanding shares of which 310.29 K shares are currently shorted by private and institutional investors with about 0.08 trading days to cover.
Biofrontera currently holds about 31.91 M in cash with (24.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Biofrontera Probability Of Bankruptcy
Ownership AllocationBiofrontera retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Biofrontera Ownership Details
Biofrontera Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Biofrontera market risk premium is the additional return an investor will receive from holding Biofrontera long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0477 | |||
| Jensen Alpha | 0.3633 | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | 0.0321 |
Biofrontera Stock Against Markets
Biofrontera Corporate Management
| Daniel JD | General Compliance | Profile | |
| Jon MBA | Vice Affairs | Profile | |
| Erica CPA | COO, CEO | Profile | |
| Jeff Holm | Head Devel | Profile | |
| Mark Baldyga | Head Marketing | Profile | |
| Alycia Torres | Vice Administration | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.